Lesinurad Intermedia CAS 1533519-85-5 Puritas >99.0% (HPLC)
Shanghai Ruifu Chemical Co., Ltd. est praecipuum fabricam Methyl 2-[[4-(4-Cyclopropylnaphthalen-1-yl)-4H-1,2,4-Triazol-3-yl]thio] acetatis (CAS: 1533519-85-5) cum qualitate media Lesinurad (CAS: 878672-00-5).Ruifu Chemical traditio totius terrarum, quantitatis competitive pretium, optimum servitium, parvas et moles in promptu habere potest.Purchase Lesinurad Intermedia,Please contact: alvin@ruifuchem.com
| Nomen chemicum | Methyl 2-[[4-(4-Cyclopropylnaphthalen-1-yl)-4H-1,2,4-Triazol-3-yl]thio]acetate |
| Synonyma | Lesinurad INT4;Lesinurad Impurity 11;Methyl {[4-(4-Cyclopropyl-1-Naphthyl)-4H-1,2,4-Triazol-3-yl]sulfanyl} acetatis |
| Stock Status | In Stock, Commercial Productio |
| CAS Number | 1533519-85-5 |
| Formulae hypotheticae | C18H17N3O2S |
| M. Pondus | 339.41 g/mol |
| Ferveret | 546.4±60.0℃ |
| Density | 1.38±0.10 g/cm3 |
| COA & MSDS | Praesto |
| Origin | Shanghai, China |
| Categoria | Intermedia Lesinurad (CAS: 878672-00-5) |
| Brand | Ruifu Chemical |
| Items | Signa inspectionis | Proventus |
| Aspectus | Off-Pulvis alba | Off-Pulvis alba |
| Puritas / Analysis Methodus | >99.0% (HPLC) | 99.6% |
| Maximae impudicitiae | <0.50% | 0.2% |
| Totalis immunditias | <1.00% | 0.4% |
| Aquae Caroli Fischer | <0.50% | 0.1% |
| Damnum in Siccatio | <0.50% | 0.1% |
| Residere in Ignition | <0.20% | 0.1% |
| Infrared Imaginis | Conformat ut Structure | Obsequitur |
| 1H NMR Imaginum | Conformat ut Structure | Obsequitur |
| conclusio | Productum probatum est et cum datis specificationibus obsequitur | |
Sarcina:Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris.
Repono Condition:Continentem arcte clausam et in loco frigido, sicco (2~8℃) reponunt et a cellis bene ventilatis ab substantiis incompossibilibus.A luce et humore protege.
Naviportans:Libera ad mundum ab aere, per FedEx / DHL Express.Ieiunium et certas traditiones provide.
Quam mercari?Quaeso contactumDr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
15 Years Experience?Plus quam XV annos experientiae habemus in fabricando et exportando amplis intermediis pharmaceuticis vel alchimicis pharmaceuticis amplis.
Mercatus principalis?Vendere mercatum domesticum, Americam septentrionalem, Europam, Indiam, Coream, Iaponicam, Australiam etc.
Commodi?Superior qualitas, parabilis pretium, officia professionalia et subsidia technica, ieiunium partus.
Qualitasfides?Qualitas strictioris temperantiae ratio.Pro instrumento analysi professionali includuntur NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, KF, ROI, LOD, MP, Claritas, Solubilitas, Microbialis limes test, etc.
Exempla?Pleraque producta praebent exempla gratuita pro qualitate aestimationis, sumptus naviculas a clientibus solvendos.
Factory Audit?Factory audit gratissimum.Quaeso ante constitutum.
MOQ?Nec MOQ.Parvus ordo placet.
Tempus adferendi? Si intus prosapia, tres dies partus praestatur.
Transportatio?Per Express (FedEx, DHL), ab Air, per Mare.
Documenta?Post servitium venditionis: COA, MOA, ROS, MSDS, etc. praeberi possunt.
Consuetudo Synthesis?Consuetudo synthesis officia praebere potest ad optimas investigationes tuas necessitates aptandas.
Pensio conditio?Proforma cautionis primum post confirmationem ordinis mittetur, informationes nostrae ripae inclusas.Payment by T/T (Telex Transfer), PayPal, Western Union, etc.
Methyl 2-[[4-(4-Cyclopropylnaphthalen-1-yl)-4H-1,2,4-Triazol-3-yl]thio]acetate (CAS: 1533519-85-5) adhibetur ut medium Lesinurad (CAS: 878672-00-5).Probatus a FDA nuper in 2015, lesinuradus est anion portator uratae commutationis 1 (URAT1) inhibitor usui in curatione podagrae.Ardea Biosciences, quae subsidiaria AstraZeneca est, lesinurades evolvit adhibendas esse in compositione therapiae cum inhibitoribus xanthine oxidasi ad curationem hyperuricaemia cum podagra coniuncta.Processus approbationis continuatur in pluribus aliis regionibus per globum, cum EMA Committee pro Products medicinalibus pro Humano Usu dans lesinurad opinionem affirmativam pro usu therapiae adjunctivae in compositione cum xanthine oxidasi inhibitoribus ad hyperuricaemia tractandum.
